Labcorp Reports Strong 2026 Third Quarter Results; Raises Full Year 2026 Guidance
Labcorp announced its third-quarter 2026 financial results, reporting a 7% year-over-year revenue increase and raising its full-year 2026 guidance.
Stocks · News reference
Labcorp, Charles River, and FDA Partner on Drug Abuse Research
Labcorp has entered into a collaborative partnership with Charles River Laboratories and the FDA to conduct research on the potential abuse of medicines.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — LABCORP HOLDINGS INC. (LH)
Filed: 2026-10-28 AccNo: 0000920148-26-000213 Size: 736 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Labcorp Partners with Waters Corporation to Expand HPV Testing
Labcorp has entered into a partnership with Waters Corporation to offer the FDA-approved BD Onclarity HPV Assay across its U.S. laboratory network starting in late 2026.